Cargando…

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics

BACKGROUND: Trace amine-associated receptor-1 (TAAR1) agonists have been proposed as potential antipsychotics, with ulotaront and ralmitaront having reached clinical trials. While ulotaront demonstrated efficacy in a recent Phase II trial, a corresponding study studies of ralmitaront failed to show...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ågren, Richard, Betari, Nibal, Saarinen, Marcus, Zeberg, Hugo, Svenningsson, Per, Sahlholm, Kristoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519813/ https://www.ncbi.nlm.nih.gov/pubmed/37549917 http://dx.doi.org/10.1093/ijnp/pyad049

Ejemplares similares

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021)

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
por: Heffernan, Michele L. R., et al.
Publicado: (2021)

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
por: Liang, Lingzhi, et al.
Publicado: (2022)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

Dopamine-induced arrestin recruitment and desensitization of the dopamine D4 receptor is regulated by G protein-coupled receptor kinase-2
por: Burström, Viktor, et al.
Publicado: (2023)

Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects
por: Zeberg, Hugo, et al.
Publicado: (2018)

The Beta-Arrestin-Biased Dopamine D(2) Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation
por: Ågren, Richard, et al.
Publicado: (2018)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
por: Begni, Veronica, et al.
Publicado: (2021)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations
por: Betari, Nibal, et al.
Publicado: (2020)

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
por: Ågren, Richard, et al.
Publicado: (2021)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Major Genetic Risk Factors for Dupuytren's Disease Are Inherited From Neandertals
por: Ågren, Richard, et al.
Publicado: (2023)

Voltage-Dependent Dopamine Potency at D(1)-Like Dopamine Receptors
por: Ågren, Richard, et al.
Publicado: (2020)

Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D(2) Receptor
por: Ågren, Richard, et al.
Publicado: (2021)

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Structural and Functional Evolution of the Trace Amine-Associated Receptors TAAR3, TAAR4 and TAAR5 in Primates
por: Stäubert, Claudia, et al.
Publicado: (2010)

Identification and characterization of cichlid TAAR genes and comparison with other teleost TAAR repertoires
por: Azzouzi, Naoual, et al.
Publicado: (2015)

Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors
por: Glyakina, Anna V., et al.
Publicado: (2021)

Analysis of Human TAAR8 and Murine Taar8b Mediated Signaling Pathways and Expression Profile
por: Mühlhaus, Jessica, et al.
Publicado: (2014)

The modifying influence of HLA class II DQB1∗06:02 on the Streptococcus and clinical phenotype correlation among anti-Ro+ mothers of children with neonatal lupus
por: Clancy, Robert M., et al.
Publicado: (2022)

V374A KCND3 Pathogenic Variant Associated With Paroxysmal Ataxia Exacerbations
por: Paucar, Martin, et al.
Publicado: (2021)

Taare Zameen Par and dyslexic savants
por: Chakravarty, Ambar
Publicado: (2009)

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine
por: Zhang, Xiaoqun, et al.
Publicado: (2018)

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Weight Monitoring and Antipsychotics: Are We Compliant With NICE Guidelines?
por: Mitchell, Byrone, et al.
Publicado: (2023)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis
por: Myken, Anders N, et al.
Publicado: (2022)

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
por: Kuvarzin, Savelii R., et al.
Publicado: (2023)

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
por: Liu, Jian-Feng, et al.
Publicado: (2018)

An E280K Missense Variant in KCND3/Kv4.3—Case Report and Functional Characterization
por: Ågren, Richard, et al.
Publicado: (2023)

Ligand with Two Modes of Interaction with the Dopamine D(2) Receptor–An Induced-Fit Mechanism of Insurmountable Antagonism
por: Ågren, Richard, et al.
Publicado: (2020)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
por: Perini, Francesca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vkshopqatt45n2sbctsg1ts33j